Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy—Review of the Literature and Future Outlook

Immune checkpoint inhibitor (ICI) therapy has revolutionized the management of various cancers with previously poor prognosis. Despite its great efficacy, the therapy is associated with a wide spectrum of immune-related adverse events (irAE) including neurological symptoms which can affect all parts...

Descripción completa

Detalles Bibliográficos
Autores principales: Möhn, Nora, Beutel, Gernot, Gutzmer, Ralf, Ivanyi, Philipp, Satzger, Imke, Skripuletz, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912719/
https://www.ncbi.nlm.nih.gov/pubmed/31653079
http://dx.doi.org/10.3390/jcm8111777

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912719/
https://www.ncbi.nlm.nih.gov/pubmed/31653079
http://dx.doi.org/10.3390/jcm8111777

Ejemplares similares